Disease · HP_0012532
Chronic pain
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Chronic pain. Diseases, record HP_0012532. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0012532
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Chronic pain
- Open Targets ID
- HP_0012532
- Other names
- Long-lasting pain
- Highest stage of its drugs
- Approval, for 13 of its 97 drugs, from DailyMed, PMDA and TTD
Source Open Targets
Drugs97
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BUPRENORPHINE | CHEMBL511142 | Small molecule | Approval | DailyMed and PMDA | 17 | 14 | 14 | Drugs and targets |
| OXYCODONE | CHEMBL656 | Small molecule | Approval | DailyMed | 17 | 11 | 10 | Drugs and targets |
| FENTANYL | CHEMBL596 | Small molecule | Approval | DailyMed | 40 | 8 | 8 | Drugs and targets |
| MORPHINE | CHEMBL70 | Small molecule | Approval | TTD | 6 | 5 | 5 | Drugs and targets |
| MORPHINE SULFATE | CHEMBL2103744 | Small molecule | Approval | DailyMed | 30 | 3 | 3 | Drugs and targets |
| TRAMADOL HYDROCHLORIDE | CHEMBL1237065 | Small molecule | Approval | DailyMed and PMDA | 49 | 2 | 2 | Drugs and targets |
| OXYCODONE HYDROCHLORIDE | CHEMBL1200890 | Small molecule | Approval | DailyMed | 18 | 1 | 1 | Drugs and targets |
| ALCOHOL | CHEMBL545 | Small molecule | Approval | DailyMed and TTD | 8 | 1 | 1 | Drugs and targets |
| TAPENTADOL HYDROCHLORIDE | CHEMBL1201777 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| DULOXETINE HYDROCHLORIDE | CHEMBL1200328 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 97
See all 97 drugsTargets150
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| OPRM1 | Mu-type opioid receptor | 26 | Mu opioid receptor agonist; Mu opioid receptor antagonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist | Approval | https://conductscience.org/library/genes/4988 | Drugs and targets |
| OPRK1 | Kappa-type opioid receptor | 11 | Kappa opioid receptor agonist; Kappa opioid receptor partial agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist | Approval | https://conductscience.org/library/genes/4986 | Drugs and targets |
| OPRD1 | Delta-type opioid receptor | 8 | Delta opioid receptor antagonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4985 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 6 | Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 6 | Norepinephrine transporter inhibitor | Approval | https://conductscience.org/library/genes/6530 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 5 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Approval | https://conductscience.org/library/genes/5743 | Drugs and targets |
| SCN9A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel protein type IX alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6335 | Drugs and targets |
| GABRA1 | GABA-A receptor; agonist GABA site | 4 | GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; agonist GABA site | 4 | GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; agonist GABA site | 4 | GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2556 | Drugs and targets |
1 to 10 of 150
See all 150 targetsTrials155
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00640042 | Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza | Phase 4 | 1,570 | 2010-02-15 | Pain | MORPHINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT00487435 | An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain | Phase 3 | 1,166 | 2010-07-23 | Pain, Osteoarthritis, Low Back Pain | TAPENTADOL | Its record names the disease | ClinicalTrials.gov |
| NCT01400139 | Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period. | Phase 3 | 922 | 2014-12-04 | Chronic Nonmalignant and Nonneuropathic Pain | HYDROCODONE BITARTRATE | Its record names the disease | ClinicalTrials.gov |
| NCT03026790 | Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study | Phase 2 | 820 | 2023-06-05 | Chronic Pain | BUPRENORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT01939366 | Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves | Phase 2 | 699 | 2019-12-26 | Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus | CEBRANOPADOL, PREGABALIN | Its record names the disease | ClinicalTrials.gov |
| NCT04571619 | HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis | Phase 2 | 643 | 2025-01-13 | End Stage Renal Disease, Chronic Pain, Opioid Dependence | BUPRENORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT00784277 | A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease | Phase 3 | 597 | 2012-02-13 | Joint Diseases, Arthritis, Osteoarthritis | OXYCODONE, TAPENTADOL | Its record names the disease | ClinicalTrials.gov |
| NCT00420992 | A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee | Phase 3 | 547 | 2009-10-30 | Osteoarthritis, Chronic Pain | MORPHINE SULFATE, NALTREXONE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01115569 | Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain | Phase 3 | 424 | 2014-04-25 | Chronic Pain | HYDROCODONE BITARTRATE | Its record names the disease | ClinicalTrials.gov |
| NCT01424566 | A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer | Phase 3 | 406 | 2018-04-23 | Pain, Advanced Cancer | NABIXIMOLS | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 155
See all 155 trialsComparisons in its trials42
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Conversion/Titration Phase vs Maintenance Treatment Phase: serious adverse events | 26 of 638 | 73 of 424 | 1,062 | NCT01115569 | Trial comparisons |
| HYD Core Study vs HYD Extension Period: serious adverse events | 80 of 922 | 6 of 106 | 1,028 | NCT01400139 | Trial comparisons |
| Active Comparator: Telecare Collaborative Management (TCM) vs Active Comparator: Integrated Pain Team (IPT): 50% Reduction in Opioid Daily Dose | 102 of 403 | 98 of 399 | 802 | NCT03026790 | Trial comparisons |
| Active Comparator: Telecare Collaborative Management (TCM) vs Active Comparator: Integrated Pain Team (IPT): deaths from any cause | 7 of 358 | 9 of 363 | 721 | NCT03026790 | Trial comparisons |
| Active Comparator: Telecare Collaborative Management (TCM) vs Active Comparator: Integrated Pain Team (IPT): serious adverse events | 109 of 358 | 109 of 363 | 721 | NCT03026790 | Trial comparisons |
| Active Comparator: Telecare Collaborative Management (TCM) vs Active Comparator: Integrated Pain Team (IPT): Pain Response | 58 of 350 | 54 of 362 | 712 | NCT03026790 | Trial comparisons |
| Active Comparator: Telecare Collaborative Management (TCM) vs Active Comparator: Integrated Pain Team (IPT): Composite Response | 17 of 350 | 17 of 362 | 712 | NCT03026790 | Trial comparisons |
| Pain Coping Skills Training vs Usual Care: deaths from any cause | 35 of 319 | 34 of 324 | 643 | NCT04571619 | Trial comparisons |
| Pain Coping Skills Training vs Usual Care: serious adverse events | 169 of 319 | 167 of 324 | 643 | NCT04571619 | Trial comparisons |
| OTR 40mg vs OXYCONTIN® 40mg: deaths from any cause | 0 of 37 | 0 of 40 | 77 | NCT03398330 | Trial comparisons |
1 to 10 of 42
See all 42 comparisons in its trialsPapers from its trials99
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0012532
GET https://conductscience.org/api/diseases/v1/HP_0012532/drugs?page=2